Post-chemotherapy neutropenic fever

There are currently no studies to support the use of Ceftazidime/amikacin-based regimen as first choice empirical treatment in patients with neutropenic fever.Demonstrate that the caftazidime/amikacin regimen is not the best empirical therapeutic approach, and could be directly impacting on longer recovery time, longer hospital stay, higher costs.